Clinical impact of a commercial multiplex pathogen panel for the detection of bacteria in sputum specimens from non-ICU patients with suspected lower respiratory tract infection
Madeline T. Gemoules, Tristan T. Timbrook, Elizabeth Neuner, Valerie Yuenger, Han Li, Sena Sayood, Tamara Krekel · 2026
Read Clinical impact of a commercial multiplex pathogen panel for the detection of bacteria in sputum specimens from non-ICU patients with suspected lower respiratory tract infection by Madeline T. Gemoules, Tristan T. Timbrook, Elizabeth Neuner, Valerie Yuenger, Han Li, Sena Sayood, Tamara Krekel (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13419426.txt.
Description
Madeline T. Gemoules and colleagues test a commercial panel that names bacteria in sputum quickly, asking whether its results actually change antibiotic care. The study covers 189 sputum samples from ward patients outside intensive care who were suspected of lower airway infection. Culture remains the standard route, yet it is slow, so broad drugs often run on guesswork.
Changes that doctors made were compared with changes that the results made possible in theory, at two points in the workup. Only 48.7 percent of possible changes were acted on after panel results, while 87.8 percent were acted on after standard culture results in the same review. That action gap, not test speed, looks like the barrier. The authors call for work on why clinicians hesitate to use rapid panel answers.
Catalog record
| CREATOR | Madeline T. Gemoules, Tristan T. Timbrook, Elizabeth Neuner, Valerie Yuenger, Han Li, Sena Sayood, Tamara Krekel |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |